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Abstract
Background: Musashi1 (Msi1) is a conserved RNA-binding protein that regulates the Notch and Wnt pathways,
and serves as a stem cell marker in the breast and other tissues. It is unknown how Msi1 relates to other breast
cancer markers, whether it denotes tumor initiating cells (TICs), and how it affects gene expression and tumor cell
survival in breast cancer cells.
Results: Msi1 expression was analyzed in 20 breast cancer cell lines and in 140 primary breast tumors by western
blotting and immunohistochemistry, respectively. Lentivirus RNA interference was used to reduce Msi1 expression
in breast cancer cell lines MCF-7 and T47D grown as spheroid cultures and to assess stem cell gene expression
and the growth of these cell lines as xenografts. In normal human breast tissue, Msi1 was expressed in 10.6% of
myoepithelum and 1.2% of ductal epithelium in the terminal ductal lobular unit (TDLU), whereas, less than 0.05%
of ductal epithelium and myoepithelium in large ducts outside the TDLU expressed Msi1. Msi1 was expressed in
55% of the breast cancer cell lines and correlated with ErbB2 expression in 50% of the cell lines. Msi1 was
expressed in 68% of primary tumors and in 100% of lymph node metastases, and correlated with 5 year survival.
Msi1 was enriched in CD133
+ MCF-7 and T47D cells and in spheroid cultures of these cells, and Msi1 ‘knockdown’
(KD) with a lentivirus-expressed shRNA decreased the number and size of spheroid colonies. Msi1 KD reduced
Notch1, c-Myc, ErbB2 and pERK1/2 expression, and increased p21
CIP1 expression, which is consistent with known
Msi1 target mRNAs. Msi1 KD also reduced the expression of the somatic and embryonic stem cell markers, CD133,
Bmi1, Sox2, Nanog and Oct4. Xenografts of MCF-7 and T47D Msi1 KD cells resulted in a marked reduction of tumor
growth, reduced Msi1 and Notch1 expression and increased p21
CIP1 expression.
Conclusion: Msi1 is a negative prognostic indicator of breast cancer patient survival, and is indicative of tumor
cells with stem cell-like characteristics. Msi1 KD reduces tumor cell survival and tumor xenograft growth,
suggesting that it may represent a novel target for drug discovery.
Introduction
Breast cancer is the second most common malignancy
and cause of cancer death among American women [1].
Despite advances in early detection, about 30% of
patients with early-stage breast cancer have recurrent
disease. Although systemic treatment of patients with
chemotherapy, hormonal therapy and immunotherapy
produce a high response rate initially, progression
invariably occurs after a variable time interval [2]. This
m a yr e s u l tf r o mas m a l ls u b p o pulation of cells, i.e.,
cancer ‘stem’ cells or tumor-initiating cells (TICs) that
exhibit a high capacity for self-renewal, and thus contri-
bute to tumor maintenance and metastasis [3], as well
as relapse and drug resistance [4].
CD133 has been implicated as a TIC marker for
malignancies of the lung [5], liver [6,7], colon [8,9],
brain [10,11]. High CD133 expression has been noted in
MCF-7 breast cancer cells that are either drug-resistant
[12] or resistant to TRAIL-mediated apoptosis [13].
CD133
+ breast cancer cells form spheroid under low
attachment conditions, and are enriched in stem cell
markers, and rapidly form tumors in NOD/SCID mice
[14]. Thus, by these criteria ,C D 1 3 3m a yb ec o n s i d e r e d
a TIC marker. Another protein associated with breast
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fied as a cell fate determinant for sensory organ devel-
opment in Drosophila [18], and subsequent studies
found the mammalian homolog to be a stem cell marker
in the brain [19,20]. Msi1 is a highly conserved RNA-
binding protein [21] that recognizes a (G/A)Un=1 - 3 AGU
motif in the 3’-untranslated region of target mRNAs,
such as Numb [22] and p21
CIP1[ 2 3 ] ,a sw e l la so t h e r
genes involved in cell cycle regulation, proliferation
and apoptosis [24]. When expressed in mammary
epithelial cells, Msi1 activated a unique gene expres-
sion pattern associated with an autocrine pathway
involving the growth factor Proliferin1 and inhibition
of the secreted Wnt pathway inhibitor, Dickkopf3
[15,16]. This led to activation of Notch and Wnt sig-
naling and mammary stem/progenitor cell proliferation.
The role of Msi1 in the etiology and progression of
breast cancer is unknown. We hypothesized that Msi1
may promote breast TIC proliferation, and hereby influ-
ence survival outcome. Here we show that Msi1 is
expressed in approximately two-thirds of primary breast
cancers, and is associated with reduced survival. Msi1
was enriched in CD133
+ MCF-7 and T47D cells, parti-
cularly when grown as spheroid cultures, and Msi1
‘knockdown’ reduced spheroid colony formation and
tumor xenograft growth. These results suggest that
Msi1 regulates TIC proliferation and is a negative prog-
nosticator for survival in breast cancer patients.
Results
Msi1 expression in breast cancer cell lines correlates with
ErbB2
Twenty human breast cancer cell lines and one immor-
talized human mammary epithelial cell line (MCF-10A)
were used for western analysis of Msi1 (Figure 1A). Ele-
ven of 20 human breast cancer cell lines (55%)
expressed Msi1, and 13 cell lines showed a strong corre-
lation between Msi1 and ErbB2 (P = 0.02) (Figure 1B).
There was no significant correlation between Msi1 and
ERa (results not shown).
Msi1 expression is increased in CD133
+ and tumor cells in
spheroid culture
Both CD44
+/CD24
- and CD133 have been used as TIC
markers for breast cancer and other malignancies. Our
results indicate that CD44
+/CD24
- cells were very rare
in T47D (0.04%) and MCF-7 (0.36%) cells (Additional
file 1, Figure S1). In contrast, CD133 was expressed in
1.7% and 6.2% of MCF-7 and T47D cells, respectively
(Figure 2A), and Msi1 mRNA was expressed predomi-
nantly in cells expressing CD133 mRNA (Figure 2B).
MCF-7 cells grown in low attachment plates formed
spheroid cultures, which were enriched for Msi1 expres-
sion in comparison to monolayer cells (Figure 2C).
Msi1 KD in MCF-7 and T47D cells reduces CD133, ErbB2,
pERK, Notch1 and ES cell markers and increases p21
CIP1
Lentivirus-mediated Msi1 KD was used to deplete Msi1
in MCF-7 and T47D cells grown in spheroid culture.
After 3 weeks of selection, cells were harvested for wes-
tern and RT-PCR analysis. Msi1 shRNA expression sig-
nificantly reduced Msi1 levels in MCF-7 and T47D cells,
and correlated with decreased CD133, ErbB2 and
pERK1/2 expression (Figure 3A); Msi1 protein levels
were reduced in MCF-7 and T47D cells by 83% and
77%, respectively, (Figure 3A, bar graph). qRT-PCR ana-
lysis confirmed reduction of CD133 mRNA in MCF-7
cells, as well as expression of the somatic and ES cell
markers, Nanog, Oct4, Sox2, c-Myc and Bmi1 (Figure
3B). These changes, with the exception of Oct4, also
occurred in T47D cells (Figure 3B). Msi1 KD reduced
Notch expression at both the mRNA and protein levels
and increased p21
CIP1 at only protein levels, and
these effects were more pronounced in MCF-7 cells
(Figure 3C, D).
Msi1 KD reduces tumor spheroid cell colony formation
MCF-7 and T47D cells stably expressing either the control
or Msi1 shRNA were seeded into 96-well ultra low attach-
ment plates at limiting cell densities ranging from 125 to
16 cells per well in order to determine the self-renewal
capacity of the TIC population [25] (Figure 4A). After
3 weeks of selection, the number of spheroid colonies was
markedly reduced in the Msi1 shRNA-transduced cells
(Figure 4A). Measurement of colony size, an indication of
progenitor cell proliferation [25], at a cell density of
Figure 1 Msi1 correlates with ErbB2 expression. A.M s i 1 ,E r b B 2 ,
ERa and b-actin were measured in 20 breast cancer cell lines and
in immortalized breast epithelial cell line MCF-10A by western
blotting. B. There is a statistically significant correlation between
Msi1 and ErbB2 (P = 0.02) by Fisher’s Exact test.
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Page 2 of 12125 cells per well was reduced by 30% (P = 0.001) in both
MCF-7 and T47D cells (Figure 4B). Dissociation of spher-
oid colonies into single cells resulted in reformation of the
spheroid colonies, indicating that this phenotype was
stable (results not shown). These data suggest that Msi1
modulates TIC proliferation to a greater extent than pro-
genitor cell proliferation. When spheroid MCF-7 cells
were dissociated with trypsin and replated in 96-well
plates as monolayers, cell growth remained slower in cells
after Msi1 KD than in control cells (Figure 4C).
Msi1 KD inhibits the growth of breast tumor xenografts
To assess tumor growth after Msi1 KD, spheroid cultures
of T47D and MCF-7 cells expressing either the non-
silencing or Msi1 shRNA were engrafted into nude mice
at either 10,000 cells/site (T47D) or 100,000 cells/site
(MCF-7) (Figure 5A). Msi1 KD in either cell line resulted
in a 50-60% reduction in tumor growth (Figure 5B). Msi1
KD was confirmed in the tumors, and was associated
with decreased Notch1 and increased p21
CIP1 protein
expression (Figure 5C) as found for cells in culture
(Figure 3C). Lower inocula of 1,000 T47D cells and
10,000 MCF-7 cells did not engraft, and may reflect an
inadequate number of TICs in these cell lines.
Msi1 expression in human breast cancers correlates
inversely with survival and directly with metastasis
The localization of Msi1 was examined in 26 adjacent
normal breast tissues to determine if Msi1 expression
was associated primarily with the terminal ductal
lobulo-alveolar unit (TDLU). In large ducts located out-
side the TDLU, Msi1 was rarely present in either ductal
epithelium (0.03%, 35/10722 cells) or myoepithelium
(0.05%, 9/1902 cells). In the TDLU however, Msi1 was
expressed in 10.6% (353/3321 cells) of myoepithelial
cells and 1.2% (117/9545 cells) of terminal ductal
Figure 2 Msi1 is enriched in breast tumor initiating cells. A. MCF-7 and T47D cells contain a CD133
+ population. Cells sorted by FACS
revealed that CD133
+ cells represented 1.7% and 6.2% of the total cell population in MCF-7 and T47D cells, respectively. B. Msi1 is expressed
predominantly in CD133
+ cells. MCF-7 and T47D cells were sorted as in A, and CD133 and Msi1 were measured by RT-PCR. C, Spheroid cultures
of MCF-7 cells are enriched in Msi1. Cells were grown for 3 weeks in ultra low attachment plates in DMEM media without serum and
supplemented with growth factors. Spheroid colonies were harvested and Msi1 expression was determined by western blotting.
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Page 3 of 12epithelium (Figure 6A). To confirm the presence of
Msi1 in myoepithelium, double immunofluorescence
was used to measure the localization of Msi1 with the
myoepithelial cell marker, smooth muscle actin (SMA)
(Figure 6B). Msi1 and SMA co-localized, indicating the
propensity of myoepithelial cells to express Msi1. To
determine the significance of Msi1 expression in pri-
mary breast cancer, tissue microarrays of 140 tumors
were analyzed by immunohistochemistry. Approximately
two-thirds of the tumors were Msi1
+, including 51%
with high Msi1 and 17% with low expression (Figure
6C). Comparison of 19 lymph node metastases with
their matched primary tumor revealed that Msi1 was
highly expressing in 84% of metastases vs. 42% of
matched primary tumors (Figure 6D, E). Analysis of
75 patients with a follow-up period ranging from 1 to
107 months revealed that 87% of patients with tumors
lacking Msi1 survived >5 years vs. 62% of patients
w h o s et u m o r sw e r eM s i 1
+ (Figure 6F). Survival in
patients with Msi1
+ tumors was 75.0 ± 6.2 months
Figure 3 Msi1 ‘knockdown’ by a shRNA preferentially reduces CD133
+ cells and stem cell marker expression. A. Lentivirus expression of
an Msi1 shRNA. Left, ‘Knockdown’ (KD) of Msi1 in MCF-7 and T47D spheroid cells by an Msi1 shRNA (Msi1 shRNA) reduces Msi1, CD133, ErbB2
and pERK expression vs. the control shRNA (Contr shRNA). Right panel, quantitation of the western blot indicates that Msi1 was reduced by 77-
84% in MCF-7 and T47D cells. B. Msi1 KD reduces stem cell marker expression in MCF-7 and T47D cells. CD133, Nanog, Oct4, Sox2, c-Myc and
Bmi1 mRNA levels were determined by qRT-PCR. All stem cell markers, with the exception of Oct4 in T47D cells, were reduced by Msi1
knockdown. C. Left panel, Msi1 KD reduces Notch1 and increases p21
CIP1 in MCF-7 and T47D spheroid cells. IC, Notch intracellular domain; FL,
full-length Notch1. Middle panel, quantitation of Notch1 expression. Right panel, quantitation of p21
CIP1 expression. D. Msi1 KD reduces Notch1
mRNA 2.7-5-fold, but not p21
CIP1, in MCF-7 and T47D spheroid cells, respectively.
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Page 4 of 12Figure 4 Msi1 knockdown reduces spheroid colony formation. MCF-7 and T47D cells were transduced with either an Msi1 shRNA (Msi1
shRNA) or control shRNA (Contr shRNA) as in Figure 3A. A. Cells were seeded at varying dilutions into 96-well ultra low attachment plates in
DMEM media without serum and supplemented with growth factors, and the number of colonies determined after 3 weeks. Msi1 KD
significantly reduces colony formation in MCF-7 and T47D cells (***P < 0.001; **P < 0.01; *P < 0.05; two-tailed Student’s t test; N = 12). B. Msi1
KD reduces spheroid colony size. Upper panel, spheroid colony morphology by fluorescence (GFP) and Brightfield microscopy; Lower panel,
colony diameter at a density of 25 cells/well. Msi1 KD significantly reduced colony size (P < 0.001; two-tailed Student’s t test; N = 10). C. After 10
days in spheroid culture, MCF-7 cells were replated as monolayer cultures and cell growth was measured by sulforhodamine B staining at 24, 48
and 72 hr. Msi1 KD reduces the growth of MCF-7 cells 50% vs. control cells (Contr shRNA). Each value represents the mean ± S.E. of 4 samples
(**P < 0.01, *P < 0.05 by the two-tailed Student’s t test.
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Page 5 of 12(mean ± SD) vs. 102.1 ± 4.8 in patients with Msi1-
tumors (P = 0.040 by the log-rank test) (Figure 6F).
Msi1 protein expression correlated with the 5-year sur-
vival events of breast cancer patients (P = 0.023) (Table
1). Analysis of the effect of Msi1 expression on survival
time with or without adjustment for age, TNM stage,
tumor grade, and tumor size in the Cox regression
model indicated that the hazard role of Msi1 was signifi-
cant. There was no statistically significant correlation
between Msi1 expression and either TNM stage, tumor
grade, ErbB2, ER, PR or p53 expression (results not
shown). Thus, Msi1 expression is a prognosticator of
TIC burden in breast cancer.
Discussion
Msi1 is an RNA-binding protein that functions as a
translational repressor [20], and is widely used as a mar-
ker of stem cells in embryonic and adult tissues [18,21].
Although Msi1 has been reported to be elevated in high
grade gliomas [26] and liver cancer [27], little is known
about its function and prognostic value. Here we report
that Msi1 is expressed in a high proportion of primary
breast cancers and cell lines, particularly in metastatic
disease. The most important prognostic factor influen-
cing the outcome of patients with invasive breast cancer
is whether the tumor has spread regionally or systemi-
cally [28], and there is evidence that TICs play an
important role in mediating metastasis. Our finding that
84% of breast cancer lymph node metastases expressed
Msi1, in comparison to 42% of matched primary
tumors, is consistent with the role of TICs in metastatic
disease. Since Msi1 predicted shorter survival as well, it
may ultimately be a useful prognostic indicator of regio-
nal spread of the disease.
In normal breast tissue, Msi1 is co-localized predomi-
nantly with myoepithelial cells in the TDLU, where
approximately 10% of the cells are Msi1
+.M s i 1h a s
been reported to be present in 0.6% of the total lobular
epithelial cells, and enriched in label-retaining cells [17],
which divide asymmetrically as stem cells [29].
Figure 5 Msi1 knockdown reduces breast tumor xenograft growth. A. Fluorescent imaging of GFP expression in MCF-7 and T47D breast
tumor xenografts in nude mice. Tumor cells transduced with either an Msi1 shRNA or control shRNA were transplanted into opposite flanks of
each animal, and after 8 weeks tumor size was visualized with a Maestro imaging instrument. B. Reduction of tumor growth by Msi1 shRNA. Bar
graphs indicate the relative changes in tumor xenograft area computed by pixel imaging. Each value represents the mean ± S.E. from five
animals; P < 0.02 and P < 0.05 for T47D and MCF-7 xenografts, respectively, by the two-tailed Students t test. C. Msi1 KD in MCF-7 and T47D
xenograft tumors reduces Msi1 and Notch1, and increases p21
CIP1 protein expression.
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Page 6 of 12Figure 6 Msi1 expression in breast cancer tissue microarrays. A. Upper panel, Msi1 is rarely expressed in large ductal epithelial cells of
normal breast tissue (red arrow), Lower panel, Msi1 is frequently expressed in terminal ductal myoepithelial cells (black arrows), whereas, one
Msi1
+ cell is present in terminal ductal epithelial cells (red arrow). B. Msi1 and smooth muscle actin (SMA) are co-expressed in terminal ductal
myoepithelial cells. C. Upper left panel, a breast cancer specimen “negative” for Msi1 expression (<1% positive cells). Upper right panel, a breast
cancer specimen with “low” Msi1 expression (1-30% positive cells). Lower Left panel, a breast cancer specimen with “high” Msi1 expression
(>31% positive cells). Lower right panel, the relative percentages of “negative”, “low” and “high” Msi1 expression in all samples (N = 140). D.
“Low” and “high” Msi1 expression in lymph node metastases. E. Msi1 is expressed in all metastatic breast cancer specimens. Bar graph indicates
that 84% of lymph node metastases (LN; N = 19) had high Msi1 expression vs. 42% of matched primary tumors (Primary BC; N = 19) and 52% of
all breast cancer specimens (Total BC; N = 140). F. Kaplan-Meier analysis indicates that a larger percentage of patients with Msi1
+ tumors
(N = 47) survive <5 years vs. patients with Msi1
- tumors (N = 28). These results suggest that Msi1 is a negative prognostic marker.
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Page 7 of 12Msi1-overexpressing mammary epithelial cells express
stem and progenitor cell markers, where Msi1 co-loca-
lizes with CK14
+ myoepithelial cells [16], a phenotype
consistent with the basal cell characteristics of mam-
mary stem cells [30]. In the present study, Masi1 was
functionally active in breast cancer cells, since inhibition
of colony expansion and tumor growth by Msi1 KD
resulted in increased Notch and reduced p21
CIP1.
Numb, a translational target of Msi1, promotes the
degradation of intracellular Notch [22], and hence Msi1
KD would reduce Notch expression (Figures 3 and 5).
p21
CIP1, an inhibitor of cyclin-dependent kinases, is a
translational target of Msi1 [23], and hence Msi1 KD
would increase its expression and stimulate growth (Fig-
ures 3 and 5). These data indicate that Notch and
p21
CIP1, among other factors, regulate the TIC capacity
of MCF-7 and T47D cells, and are consistent with the
growth inhibitory activity of Msi1 KD in medulloblas-
toma [31] and colon tumor [32] cells.
CD44
+/CD24
- and CD133 have been reported as TIC
markers for breast cancer [5-11,13,14,36-38]. CD44
+/CD24
-
cells represented a very small percentage (0.02-0.36%) of
MCF-7 and T47D cells [33] (Additional file 1, Figure S1).
In contrast, CD133 was expressed in 1.7-6.2% of the cells,
which were also enriched in Msi1. Msi1 was also enriched
in spheroid cells, which have been reported to be less sensi-
tive to ionizing radiation than monolayer cells and exhibit
reduced senescence [34,35]. Mammary dysplasia induced
by constitutively active hedgehog signaling also leads to an
expansion of murine stem cells as high as 15-33% with an
increased proliferative capacity [36]. Similar findings of an
increased tumorigenic capacity have been reported for
spheroid breast cancer cells in pleural effusions [37]. Thus,
the capacity to form anchorage-independent spheroid cells
reflects the TIC capacity of tumor cells, and is consistent
with our tumor xenograft data.
In addition to affecting TIC proliferation, Msi1 regu-
lated the expression of several somatic and ES cell
markers, including CD133, Bmi1, Nanog, Oct4, Sox2
and c-Myc (Figure 3). Although, CD133 is TIC marker
[5-11,13,14,38], its function in this context is largely
unknown. Bmi1 is a polycomb protein that plays a cri-
tical role in somatic stem cell self-renewal based on
gain-of-function and loss-of-function analyses [39,40].
Oct4, Sox2, Nanog and Lin-28 [41], as well as Oct3/4,
Sox2, Klf4, and c-Myc [42] were shown to induce plur-
ipotent stem cells from human fibroblasts. An ES cell
gene signature has also been reported in poorly differ-
entiated breast cancers and other tumors, and corre-
lated with poor survival [43]. Thus, Msi1 appears to
regulate transcriptional pathways required for survival
and maintenance of the undifferentiated state.
Previously, Msi1 was found to activate an autocrine
process in mammary epithelial cells that resulted in pro-
genitor cell expansion through proliferin-mediated acti-
vation of ERK and Wnt and Notch signaling [15,16].
These findings are in agreement with the reduction of
pERK1/2 and Notch1 expression after Msi1 KD. Wnt
and ERK signaling constitute an oncogenic positive feed-
back loop [44], and inhibition of these pathways led to
the differentiation of ES cells [16]. It therefore seems
likely that activation of Wnt signaling through ERK by
Msi1 plays a similar role in the maintenance of TIC
proliferation and the undifferentiated state [15,16].
There was also a correlation between Msi1 and ErbB2
expression. ErbB2 was reduced in cells after Msi1 KD,
suggesting that either ErbB2-expressing cells are only
affected or that Msi1 acts downstream of ErbB2 signal-
ing. ErbB2 is notable for its role in the pathogenesis of
breast cancer and as a therapeutic target, and is fre-
quently associated with metastatic disease and tumor
progression [45]. Recently, ErbB2 was shown to induce
Notch1 activity in breast cancer cells [46], which is con-
sistent with its ability to drive mammary stem cell pro-
liferation, tumorigenesis and invasion [47]. Since Msi1
activates the Notch pathway by directly targeting Numb,
our findings suggest a common endpoint between the
Msi1 and ErbB2 pathways that merits further examina-
tion in a larger subset of patients.
Conclusion
Msi1 plays a role in the proliferation of breast TICs that
denotes a more metastatic, and presumably, a therapy-
resistant cell population that reflects poor outcome.
Future studies will address if Msi1 may serve as a TIC-
selective therapeutic target for breast cancer and other
malignancies.
Methods
Cell Lines
Human breast cancer cell lines BRC-230, BT20, BT483,
BT474, BT549, DU4475, Hs578T, MCF-7, MDA-MB-
134VI, MDA-MB-157, MDA-MB-231, MDA-MB-330,
MDA-MB-361, MDA-MB-415, MDA-MB-435,
Table 1 Msi1 correlates with five year survival
Msi1 P
Negative Low High
Survival Year >5 18 9 19 0.023
<5 1 5 13
Stage 0 0 0 1 0.446
II 18 7 19
III 10 10 19
Grade I 3 0 4 0.126
II 14 5 20
III 10 12 13
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75-1, and immortalized human mammary epithelial cell
line MCF-10A were obtained from the Tissue Culture
Shared Resource, Lombardi Comprehensive Cancer
Center. MCF-7 and T47D cells were maintained in Dul-
becco’s- modified Eagle’s medium (DMEM) (Sigma-
Aldrich Chemical Co., St. Louis, MO) supplemented
with 10% fetal bovine serum at 37°C under 5% CO
2 in a
Sanyo CO2 incubator.
Western Blotting
Cells lysates were prepared on ice [48], and protein con-
centration was determined using the Bicinchonic Acid
Assay (Pierce, Rockford, IL). Cell lysates (20 μgp r o t e i n )
were separated in Criterion XT Bis-Tris Gels (Bio-Rad),
transferred to a polyvinylidene difluoride membrane
(Amersham Biosciences, Piscataway, NJ) and separated in
the Criterion System (Bio-Rad, Hercules, CA). Proteins
were detected with the appropriate primary antibody
using horseradish peroxidase-linked secondary antibo-
dies, and visualized by chemiluminescence with the West
Pico system (Amersham Biosciences, Piscataway, NJ).
Primary antibodies included rat anti-Msi1 or anti-bioti-
nylated Msi1 (1:1000) [49] (14H-1, Dr. Hideyuki Okano,
Keio University, Tokyo, Japan), rabbit anti-ErbB2
( 1 : 1 0 0 0 )( M i l l i p o r e ,D a n v e r s ,M A ) ,m o u s ea n t i - E R a
(1:200, Santa Cruz Biotechnology, Santa Cruz, CA), rab-
bit anti-CD133 (1:1000) (Cell Signaling Technology, Dan-
vers, MA), rabbit anti-pERK1/2 (1:1000)(Cell Signaling
Technology), mouse anti-b-actin (1:5000) (Sigma-Aldrich
Corp), rabbit anti-Notch1(D1E11) (Cell Signaling Tech-
nology) and mouse anti-p21
CIP1 (EMD Chemicals,
Gibbstown, NJ).
Flow Cytometry
For CD133, CD24 and CD44 detection, MCF-7 and T47D
cells were suspended at a concentration of 0.5-1.0 × 10
6
cells/ml in ice-cold PBS containing 3% fetal bovine serum
(PBS/FBS). One μg of CD133 unconjugated primary anti-
body (Cell Signaling Technology), CD24-biotin or CD44-
phyoerythrin(PE)-Cy5 (eBioscience, Inc. San Diego, CA)
or control IgG isotype antibody was incubated with
10
6 cells on ice for 60 min. Cells were washed three times
by centrifugation at 400 × g for 5 min, and resuspended
in ice-cold PBS/FBS. CD24 was measured with FITC-
conjugated streptavidin (eBioscience) (1:100 dilution) after
incubation for 45 min. CD133 was measured with an anti-
rabbit secondary antibody conjugated with PE after incu-
bation at room temperature for 45 min. Cells were sorted
with a Becton Dickinson FACSort system into CD133
+
and CD133
- cell populations and analyzed with FCS
Express V3 software (De Novo Software, Ontario,
Canada). Cells were washed twice with PBS and the cell
pellet stored at -80°C for RT-PCR.
Lentivirus-mediated shRNA Expression
Msi1 expression was ‘knocked down’ using an shRNA-
mir GIPZ lentiviral vector targeting the sequence,
5′-CGT-CCT-GTA-TCA-TAT-GTA-AAT-3′ in the
3′-UTR of Msi1 mRNA (Oligo ID # V2HS_280120;
Open Biosystems, Huntsville, AL) [31]. TLA-HEK293T
cells (Open Biosystems) were transfected with the
Trans-Lentiviral Packaging Mix and pGIPZ transfer vec-
tor at 50% confluence using Arrest-In transfection
reagent (Open Biosystems) according to the manufac-
turer’s protocol. After incubation for 48-72 hr, the
virus-containing supernatant was collected and centri-
fuged at 3,000 rpm for 20 min at 4°C, mixed 50:50 with
fresh cell culture media, and used to transduce MCF-7
and T47D cells. Lentivirus expressing either a non-
silencing control shRNA (shRNAmir, Open Biosystems)
served as a negative control. Cells were selected
for stable integration of the virus by incubation with
2.5 μg/ml puromycin (Sigma-Aldrich Corp.) for 10 days.
The efficiency of integration was monitored by green
fluorescent protein (GFP) co-expressed by the lentivirus.
RT-PCR
RNA was extracted using an RNeasy mini kit (Qiagen,
Valencia, CA) using the manufacturer’sp r o t o c o l .O n e
μg RNA was reverse-transcribed in a total volume of 20
μl using the Omniscript RT kit (Qiagen). PCR was per-
formed in triplicate using an ABI-Prism 7700 instru-
ment (Applied Biosystems, Foster City, CA) and SYBR
Green I detection (Applied Biosystems) according to the
manufacturer’s protocol. Amplification using the appro-
priate primers (Additional file 2, Table S1) was con-
firmed by ethidium bromide staining of the PCR
products in an agarose gel. The expression of each tar-
get gene was normalized to the expression of 18S RNA
and is presented as the ratio of the target gene to 18S
RNA, expressed as 2
-ΔCt, where Ct is the threshold cycle
and ΔCt = Ct
Target -C t
18S as described previously[16].
Spheroid Cell Culture
Spheroid cell culture was carried out in ultra low attach-
ment plates as described with small modifications [25].
Briefly, MCF-7 and T47-D cells growing as monolayer
cultures were trypsinized with 0.05% trypsin-0.5 mM
EDTA (Invitrogen, Carlsbad, CA), washed twice with
PBS, counted and seeded into a 6-well plate at a density
of 3,000 viable cells/ml or into a 96-well plate at serial
dilutions of 125 to 16 cells per 200 μl. Cells were grown
in serum-free DMEM medium supplemented
with 1× B27 (Invitrogen), 20 ng/ml EGF (Sigma) and
20 ng/ml FGF-2 (Invitrogen) at 37°C under 5% CO2.
Spheroid clusters were counted and collected by gravity
or gentle centrifugation (800 g, 10 sec) after 21 days,
and dissociated in 0.05% trypsin-0.5 mM EDTA for
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a4 0 - μm nylon mesh sieve (Falcon), analyzed microsco-
pically for single cellularity and counted. Successive pas-
sages were plated at 1,000 cells/ml in 6-well plates and
colony size quantitated using MetaMorph software.
Growth Assay
Cells were seeded in 96-well plates at 5,000 cells/well in
200 μl medium, and growth was determined 24 to 72 h
later by sulforhodamine B staining [50]
Tissue Microarrays
Breast cancer tissue microarray slides were obtained
from Imgenex (San Diego, CA, Cat# IMH-371 and
IMH-364), US Biomax (Rockville, MD, Cat#BR951) and
Cybrdi (Xian, China, cat# CC08-01). There were a total
of 140 cases of primary breast cancer, 19 metastatic
lymph node carcinomas and 24 normal adjacent breast
tissues. All patients were female between 20 and
84 years of age, with a median age of 47. Eighty four of
140 cases contained TNM stage data, 78 of 140 cases
contained ER, PR and p53 status, and 40 of 110 cases
were analyzed for ErbB2 expression (Table 1). After
diagnosis, 75 of 140 patients were followed up for 1 to
107 months, with a median follow-up time of 76
months, and 11 were deceased by 60 months.
Immunohistochemistry
Tissue microarray slides were baked at 62°C for 1 hr,
deparaffinized in xylene for 15 min, and rehydrated in
100%, 95% and 70% ethanol for 5 min each. Antigen
retrieval was achieved by steaming slides for 10 min in
10 mM citrate buffer, pH 6.0. Slides were washed three
times in PBS and blocked for 1 hr in a buffer containing
10% goat serum in PBS, and incubated overnight at 4°C
with a 1:1,000 dilution of rat anti-Msi1 antibody 14H-1
conjugated with biotin [49]. Slides were washed three
times in PBS and antigen visualized with ABC Vectas-
tain and DAB as substrate (Vector Labs, Burlingame,
CA). Slides were counterstained with Harris-modified
hematoxylin (Thermo-Fisher, Pittsburgh, PA) and
mounted in Permount. The level of Msi1 expression in
breast cancer tissue was categorized as negative, low
(1~30% positive) and high (>31% positive). Four high
power fields (400×) were randomly chosen for counting
Msi1
+ cells in each core of the slides. The total cell
number counted was ~1000 per core per patient. All
slides were reviewed by one pathologist (Linnoila RI,
MD) and one well-trained researcher in pathology
(Wang XY, MD, PhD) blinded to the patients’ clinical
information. The agreement between the two research-
ers for the determinations of all tumor samples was
90.7% with a 0.76 of Cohen’s Kappa indicating
substantial agreement.
Dual Label Immunofluorescence
Dual label immunofluorescence was performed using
methods similar to those described previously [16]. The
primary antibodies used were: mouse monoclonal anti-
human smooth muscle actin (SMA) (clone 1A4, Dako
North America, Inc. Carpinteria, CA) and rat monoclo-
nal anti-mouse Msi1 antibody 14H-1 [49]. Antigens
were retrieved as described above, and detected sequen-
tially on sections by incubation for 1 hr with the first
(Msi1) primary antibody followed by incubation with
the appropriate PE-conjugated streptavidin (eBioscience,
Inc), and then incubation for 1 hr with the second pri-
mary antibody followed by FITC-conjugated secondary
antibodies. All incubations were at room temperature
and sections were washed in PBS (3 × 5 min) between
each step. Sections were mounted in an anti-fading
reagent with 4′,6-diamidino-2-phenylindole (DAPI)
(Invitrogen). Control slides were included in each analy-
sis in which non-immune serum was substituted
for primary antibodies and secondary antibodies
individually.
Tumor Xenografts
MCF-7 and T47D cells were grown as spheroid cultures
and transduced with either the non-silencing shRNA or
Msi1 shRNA as described above. Ten athymic nu/nu
female mice of 6 weeks of age were each injected s.c.
with a 60-day release pellet containing 0.72 mg 17-b-
estradiol. Five animals were then injected s.c. into oppo-
site flanks with either 100,000 MCF-7 cells transduced
with a non-silencing shRNA or MCF-7 cells transduced
with the Msi1 shRNA mixed with 0.45 mg Matrigel (BD
Biosciences, Inc.). The same protocol was used for xeno-
grafts of T47D cells except that the inoculum was
10,000 cells. The frequency of engraftment of MCF-7
and T47D cells at these inocula was approximately 80%,
which is similar to what is observed for standard xeno-
graft procedures using inocula of ~5 × 10
6 cells. After
8 weeks, tumor size was imaged for GFP fluorescence
using a Maestro imaging system (Cambridge Instru-
ments, Inc.) with 1-3% isofluorane in oxygen as
anesthetic.
Statistics
Fisher’se x a c tt e s tw a su s e dt oa n a l y z et h ec o r r e l a t i o n
between Msi1 and ErbB2 protein expression in breast
cancer cell lines. Fisher’s exact two-tailed test was also
used to determine the association between Msi1 and the
clinic stage, grade and 5-year survival events in breast
cancer patients. Student’s t test was used to determine
the significance of the differences between cell growth,
spheroid cell number and sphere diameters in cell lines,
as well as tumor size resulting from Msi1 KD. The
Kaplan-Meier method, log rank test and Cox regression
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expression on the overall survival of patients with breast
cancer. All tests were two-sided and determined with
SAS software (version 9.1; SAS Institute, Cary, NC,
USA). P < 0.05 was considered statistically significant.
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